CVRx Expands Heart Failure Device Trial, Boosting Stock

CVRx’s Barostim device is set to be tested in an expanded heart failure patient population, driving a nearly 20% rise in the company’s stock. The BENEFIT-HF trial (NCT07232030) will enrol 2,500 patients across roughly 150 centers in the U.S. and Germany, focusing on those who remain symptomatic despite optimized guideline-directed medical and device therapies, with left ventricular ejection fraction (LVEF) <50% or NT-proBNP <5,000 pg/mL.

Barostim is an implantable neuromodulation device that stimulates carotid artery baroreceptors, enhancing baroreflex signaling, rebalancing the autonomic nervous system, and alleviating heart failure symptoms. Approved by the FDA in 2019 for patients with LVEF <35% or NT-proBNP <1,600 pg/mL, it is also commercially available in Europe.

If BENEFIT-HF succeeds, the trial could triple the indicated patient population, broadening access to Barostim. The primary endpoint will track all-cause mortality and heart failure decompensation events, reinforcing CVRx’s leadership in neuromodulation-based heart failure care.

25-01-2026